Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $587000.0.

  • Cytek Biosciences' Change in Receivables fell 9061.1% to $587000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 16760.33%. This contributed to the annual value of $5.4 million for FY2024, which is 2596.84% down from last year.
  • As of Q3 2025, Cytek Biosciences' Change in Receivables stood at $587000.0, which was down 9061.1% from -$652000.0 recorded in Q2 2025.
  • Cytek Biosciences' Change in Receivables' 5-year high stood at $9.3 million during Q4 2024, with a 5-year trough of -$6.4 million in Q1 2025.
  • Its 5-year average for Change in Receivables is $2.0 million, with a median of $1.0 million in 2022.
  • As far as peak fluctuations go, Cytek Biosciences' Change in Receivables plummeted by 68333.33% in 2023, and later skyrocketed by 364714.83% in 2024.
  • Cytek Biosciences' Change in Receivables (Quarter) stood at $720000.0 in 2021, then skyrocketed by 1006.11% to $8.0 million in 2022, then plummeted by 103.3% to -$263000.0 in 2023, then soared by 3647.15% to $9.3 million in 2024, then plummeted by 93.71% to $587000.0 in 2025.
  • Its Change in Receivables stands at $587000.0 for Q3 2025, versus -$652000.0 for Q2 2025 and -$6.4 million for Q1 2025.